October 01, 2025

Remibrutinib Gains FDA Nod for Urticaria

First oral BTK inhibitor approved for antihistamine-resistant chronic spontaneous urticaria, targeting mast cell–driven immune dysregulation

Conexiant

September 19, 2025

New Topical JAK Inhibitor Option for Kids

The FDA approved ruxolitinib cream for children aged 2 to 11 with mild to moderate atopic dermatitis.

Conexiant

September 17, 2025

Global Survey Finds Suicidal Ideation Risk With Atopic Eczema

Obesity, severe disease, and insomnia raise suicidal ideation risk in atopic eczema

Conexiant

September 16, 2025

Lebrikizumab 24-Week Trial in Skin of Color Atopic Dermatitis

Lebrikizumab shows sustained efficacy across Fitzpatrick IV–VI at 24 weeks in atopic dermatitis.

Conexiant

September 12, 2025

FDA Considers Ending Routine Advisory Committees on New Drugs

The FDA move to limit advisory committee involvement in drug approvals has prompted debate on the balance between efficiency and transparency.

KFF Health News

April 26, 2024

Wildfires May Have Triggered Skin Disease Flare-ups in Northeastern United States

The number of visits to dermatologists for atopic dermatitis and eczema may have increased during the summer months of 2023 following the Canadian wildfires.

Conexiant

July 02, 2024

Black Docs Lacking Amid Growing Attacks on Diversity Programs

Research has shown that patients of color prefer seeing doctors of their own race — and some studies have shown health outcomes are better for Black patients seeing Black doctors.

KFF Health News

July 17, 2024

Cendakimab Shows Promise in Phase II Trial for Atopic Dermatitis

Discover the potential of cendakimab, an anti–interleukin-13 monoclonal antibody, to improve symptoms in adult patients with moderate to severe atopic dermatitis, as demonstrated in a recent phase II clinical trial published in JAMA Dermatology.

Conexiant

January 07, 2025

Patient Insights on HRQOL in Chronic GVHD

Explore how cutaneous graft-versus-host disease impacts patients’ quality of life across physical, psychological, and social domains.

Conexiant